Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. D. Boral Capital's target price would indicate a potential upside of 70.77% from the company's previous close.
Several other research analysts have also issued reports on the stock. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. HC Wainwright upgraded shares of Urogen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price target for the company in a research note on Monday, June 16th. Guggenheim restated a "buy" rating and set a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the company a "buy" rating in a research note on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the company a "neutral" rating in a research note on Friday, June 13th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $32.86.
Read Our Latest Stock Report on URGN
Urogen Pharma Stock Up 6.0%
Shares of NASDAQ:URGN traded up $0.83 on Monday, hitting $14.64. The company had a trading volume of 1,457,274 shares, compared to its average volume of 1,091,737. The firm's 50-day simple moving average is $9.82 and its two-hundred day simple moving average is $10.31. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $18.15. The firm has a market capitalization of $675.05 million, a price-to-earnings ratio of -4.60 and a beta of 1.02.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analysts' expectations of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. Equities research analysts anticipate that Urogen Pharma will post -3.12 EPS for the current year.
Insider Activity
In other news, insider Mark Schoenberg sold 5,162 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the sale, the insider owned 153,378 shares of the company's stock, valued at $1,130,395.86. This trade represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.10% of the stock is currently owned by insiders.
Institutional Trading of Urogen Pharma
A number of institutional investors have recently made changes to their positions in the stock. CWM LLC boosted its holdings in shares of Urogen Pharma by 6,047.1% in the first quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after buying an additional 5,140 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Urogen Pharma in the fourth quarter worth approximately $59,000. Lazard Asset Management LLC purchased a new position in shares of Urogen Pharma in the fourth quarter worth approximately $67,000. GAMMA Investing LLC boosted its holdings in shares of Urogen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after buying an additional 7,392 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in shares of Urogen Pharma in the fourth quarter worth approximately $101,000. Hedge funds and other institutional investors own 91.29% of the company's stock.
About Urogen Pharma
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Further Reading
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
